BioNexus Gene Lab Corp - Common stock (BGLC) earnings
BGLC earnings moved a median of 0.00% by the close. Quarterly and annual BGLC reports and results, each read against the price at its own news timestamp. Back to the BGLC overview →
25 measured BGLC earnings events.
Where these BGLC earnings landedvs 24 measured BGLC earnings reactions
| Middle 50% of BGLC earnings reactions | -2.14% to +3.50% |
|---|---|
| Median reaction (to close) | 0.00% |
| Measured reactions | 24 |
Point-in-time · zero look-ahead
Half of the 24 BGLC earnings events with a measured close landed between -2.14% and +3.50%; 42% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q BioNexus Gene Lab Corp For: Jun 30 | SEC filing · Form 10-Q | -4.91% | -2.39% | |
| Form 10-Q BioNexus Gene Lab Corp For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +5.56% | |
| Form 10-K BioNexus Gene Lab Corp For: Dec 31 | SEC filing · Form 10-K | +0.00% | -5.63% | |
| Form NT 10-K BioNexus Gene Lab Corp For: Dec 31 | SEC filing · Form NT | — | +4.13% | |
| Form 10-Q BioNexus Gene Lab Corp For: Sep 30 | SEC filing · Form 10-Q | -1.32% | +3.54% | |
| Form 10-Q BioNexus Gene Lab Corp For: Jun 30 | SEC filing · Form 10-Q | +0.00% | — | |
| Form NT 10-Q BioNexus Gene Lab Corp For: Jun 30 | SEC filing · Form NT | +2.71% | +3.49% | |
| Form 10-Q BioNexus Gene Lab Corp For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -2.06% | |
| Form 10-K/A BioNexus Gene Lab Corp For: Dec 31 | SEC filing · Form 10-K | — | -1.66% | |
| BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory | Press release | +1.22% | +7.72% | |
| Form 10-K BioNexus Gene Lab Corp For: Dec 31 | SEC filing · Form 10-K | -1.58% | +4.74% | |
| Form NT 10-K BioNexus Gene Lab Corp For: Dec 31 | SEC filing · Form NT | +1.68% | +14.94% | |
| Form 10-Q BioNexus Gene Lab Corp For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +0.86% | |
| Form NT 10-Q BioNexus Gene Lab Corp For: Sep 30 | SEC filing · Form NT | — | -6.25% | |
| Form 10-Q BioNexus Gene Lab Corp For: Jun 30 | SEC filing · Form 10-Q | — | +0.00% | |
| Form 10-K/A BioNexus Gene Lab Corp For: Dec 31 | SEC filing · Form 10-K | — | +0.00% | |
| Form 10-Q/A BioNexus Gene Lab Corp For: Jun 30 | SEC filing · Form 10-Q | — | +0.00% | |
| Form 10-Q/A BioNexus Gene Lab Corp For: Mar 31 | SEC filing · Form 10-Q | — | +0.00% | |
| Form 10-Q/A BioNexus Gene Lab Corp For: Sep 30 | SEC filing · Form 10-Q | — | +0.00% | |
| Form 10-Q BioNexus Gene Lab Corp For: Mar 31 | SEC filing · Form 10-Q | -0.21% | -0.21% | |
| Form 10-K BioNexus Gene Lab Corp For: Dec 31 | SEC filing · Form 10-K | — | -3.08% | |
| Form NT 10-K BioNexus Gene Lab Corp For: Dec 31 | SEC filing · Form NT | +1.16% | -8.96% | |
| Form 10-Q/A BioNexus Gene Lab Corp For: Sep 30 | SEC filing · Form 10-Q | +0.58% | +2.04% | |
| Form 10-Q BioNexus Gene Lab Corp For: Sep 30 | SEC filing · Form 10-Q | -3.90% | -8.31% | |
| Form NT 10-Q BioNexus Gene Lab Corp For: Sep 30 | SEC filing · Form NT | — | +1.47% |
Keep exploring
More BGLC: analyst actions → · SEC filings → · BGLC overview →